Chennai, August 17, 2021: Caplin Steriles Ltd, a subsidiary of Caplin Point Laboratories Ltd, has received approval from Brazil’s National Health Surveillance Agency ANVISA (Agência Nacional de Vigilância Sanitária) for its sterile injectable manufacturing site near Chennai, Tamilnadu. The approval grants access to the company to register and market its products in Brazil, the largest Pharmaceutical market in Latin America.
Mr. C. C. Paarthipan, Chairman of Caplin Point Laboratories Limited commented “Brazil is an important target for Caplin Steriles’ mid to long term expansion plans. As a first step, we will focus on extending our US approved products for Brazil.”